Back to top
more

Vir Biotechnology (VIR)

(Delayed Data from NSDQ)

$8.02 USD

8.02
177,764

+0.07 (0.82%)

Updated Apr 22, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for VIR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,536 2,415 717 745 390
Receivables 0 0 773 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 53 104 73 28 13
Total Current Assets 1,588 2,519 1,563 772 403
Net Property & Equipment 96 106 43 18 16
Investments & Advances 105 24 201 0 24
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 40 50 50 51 53
Deposits & Other Assets 19 21 10 16 16
Total Assets 1,919 2,802 1,954 919 512
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 6 6 7 5 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 104 489 237 77 27
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 65 16 98 17 27
Total Current Liabilities 175 511 341 99 59
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 56 22 7 16
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 40 33 25 29 13
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 329 724 522 202 88
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,829 1,710 1,572 1,385 793
Retained Earnings -238 377 -139 -667 -369
Other Equity -1 -9 -1 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,590 2,078 1,432 717 424
Total Liabilities & Shareholder's Equity 1,919 2,802 1,954 919 512
Total Common Equity 1,590 2,078 1,432 717 424
Shares Outstanding 134.50 133.10 130.80 127.30 109.60
Book Value Per Share 11.82 15.61 10.95 5.63 3.87

Fiscal Year End for Vir Biotechnology, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,536 1,710 1,861 2,261
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 53 59 86 98
Total Current Assets NA 1,588 1,769 1,946 2,359
Net Property & Equipment NA 96 99 104 104
Investments & Advances NA 105 40 52 49
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 40 42 43 50
Deposits & Other Assets NA 19 22 24 23
Total Assets NA 1,919 2,045 2,244 2,666
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 6 4 12 12
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 104 146 198 456
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 65 15 16 17
Total Current Liabilities NA 175 165 226 485
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 2 53 53 56
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 37 37 32
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 329 370 434 695
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,829 1,799 1,772 1,738
Retained Earnings NA -238 -122 42 236
Other Equity NA -1 -2 -3 -3
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,590 1,675 1,810 1,971
Total Liabilities & Shareholder's Equity NA 1,919 2,045 2,244 2,666
Total Common Equity 0 1,590 1,675 1,810 1,971
Shares Outstanding 134.50 134.50 134.50 134.20 133.90
Book Value Per Share 0.00 11.82 12.45 13.49 14.72